Life Sciences Transactions

Experience Highlights

• AstraZeneca in agreements for the funding and global distribution of the University of Oxford's potential COVID-19 vaccine, as well as in the establishment of its global manufacturing and supply chain for the vaccine, including agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance (Gavi), the Serum Institute of India (SII), the Biomedical Advanced Research and Development Authority (BARDA) in the US, and the governments of Germany, France, Italy, and the Netherlands.

• Sanofi in a long-term research collaboration with Kymera Therapeutics to discover, develop and commercialize first-in-class protein degrader therapies for patients with immune-inflammatory diseases.

• Alcon, the global leader in eye care, in its acquisition of PowerVision, a medical device company focused on creating fluid-based intraocular lens implants for cataract patients.

• Carestream Health in the sale of its healthcare information systems (HCIS) business to Royal Philips, a global leader in health technology.

• ​​​​​​​Novartis in the $463 million sale to Mylan of its global cystic fibrosis products, including the TOBI® Podhaler and TOBI® solution.

• Pfizer in the acquisition of Therachon Holding AG, a privately held clinical-stage biotechnology company focused on rare diseases.

• Pfizer in the joint creation of Cerevel Therapeutics (a new biopharmaceutical company focused on developing drug candidates to treat central nervous system disorders) with Bain Capital whereby Pfizer contributed a portfolio of pre-commercial neuroscience assets to Cerevel in return for a 25% equity position in the company, while Bain Capital committed initial funding with the ability to provide additional capital.